Drug Profile


Alternative Names: AMG-416; Etelcalcetide hydrochloride; KAI-4169; KAI-4169-HCl; ONO-5163; Parsabiv; Telcalcetide; Velcalcetide; Velcalcetide hydrochloride

Latest Information Update: 26 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator KAI Pharmaceuticals
  • Developer Amgen; Ono Pharmaceutical
  • Class Disulfides; Peptides
  • Mechanism of Action Calcium-sensing receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Secondary hyperparathyroidism

Most Recent Events

  • 26 Jun 2017 Amgen completes a phase III extension trial for Secondary hyperparathyroidism (in patients with CKD on haemodialysis) in USA, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, the Netherlands, New Zealand, Poland, Portugal, Russia, Spain, Sweden, Switzerland and Turkey (IV) (NCT02102204)
  • 05 Jun 2017 Ono Pharmaceutical initiates a clinical trial in Secondary hyperparathyroidism in Japan (UMIN000027637)
  • 15 Mar 2017 Phase-I clinical trials in Secondary hyperparathyroidism (In children, In adolescents) in Germany, Poland (IV) (NCT02833857)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top